Medy-Tox Inc. (KOSDAQ:086900)

Market Cap	892.21B
Revenue (ttm)	241.80B
Net Income (ttm)	21.84B
Shares Out	7.02M
EPS (ttm)	3,398.79
PE Ratio	37.40
Forward PE	37.28
Dividend	1,200.00 (0.95%)
Ex-Dividend Date	Sep 29, 2025

Volume	21,140
Average Volume	33,058
Open	126,600
Previous Close	126,600
Day's Range	125,300 - 127,100
52-Week Range	112,100 - 182,700
Beta	0.16
RSI	58.24
Earnings Date	Nov 13, 2025

About Medy-Tox

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hya...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 718
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086900

Financial Performance

In 2024, Medy-Tox's revenue was 228.62 billion, an increase of 3.39% compared to the previous year's 221.12 billion. Earnings were 15.98 billion, an increase of 82.00%.